News

CHICAGO — Trastuzumab deruxtecan plus pertuzumab showed significant improvement in PFS compared with taxane chemotherapy plus trastuzumab and pertuzumab across patients with HER2-positive ...
WILMINGTON, Del., June 02, 2025--Positive results from the DESTINY-Breast09 Phase III trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated a highly statistically ...
The PFS benefit for ENHERTU plus pertuzumab versus THP was consistent across subgroups, including the prespecified stratification factors of de novo or recurrent disease, hormone receptor (HR ...
The breast cancer drug pertuzumab when added to Herceptin improved the treatment of women with early-stage, HER-2 positive breast cancer, researchers reported Friday at the annual meeting of the ...
First-line treatment with fam-trastuzumab deruxtecan-nxki + pertuzumab improved PFS in patients with HER2-positive metastatic breast cancer.
The combination of pertuzumab and trastuzumab had superior antitumor activity in women with early HER2-positive breast cancer, according to Phase II study results of the NeoSphere neoadjuvant trial.
Patients with HER2-positive breast cancer that has spread to other parts of their body live around 16 months longer if treated with a combination of pertuzumab, trastuzumab and chemotherapy ...
Pertuzumab was well tolerated, but at interim analysis, the researchers observed no prostate-specific antigen declines of greater than 50%, and recruitment was stopped.
Pertuzumab is the first investigational medicine developed to specifically prevent the HER2 receptor from pairing with other HER receptors (EGFR/HER1, HER3 and HER4).
Pertuzumab plus trastuzumab showed positive signal of activity in patients with colorectal cancer with ERBB2 amplification @ASCO #TAPUR.
4.1 The appraisal committee reviewed the data available on the clinical and cost effectiveness of pertuzumab plus trastuzumab and docetaxel, having considered evidence on the nature of human epidermal ...
ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival vs. THP as 1st-line ...